A Phase II Study of Capecitabine Plus Oxaliplatin (XELOX): A New First-Line Option in Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

A Phase II Study of Capecitabine Plus Oxaliplatin (XELOX): A New First-Line Option in Metastatic Colorectal Cancer

Published:2005 Issue:2 Volume:35 Page:103-110
ISSN:1537-3649
Container-title:International Journal of Gastrointestinal Cancer
language:en
Short-container-title:IJGC

Author:

Makatsoris Thomas,Kalofonos Haralabos P.,Aravantinos Gerasimos,Papadimitriou Christos,Kastritis Efstathios,Rigatos Sotirios K.,Xiros Nikolaos,Petsas Theodore,Economopoulos Theofanis,Sakadamis Athanassios K.,Fountzilas George

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Endocrinology,Oncology

Link

http://www.springerlink.com/index/pdf/10.1385/IJGC:35:2:103

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effect of a chemotherapy drug cocktail on myotube morphology, myofibrillar protein abundance, and substrate availability;Physiological Reports;2021-07

2. Comparison of hyperthermic intraperitoneal chemotherapy regimens for treatment of peritoneal-metastasized colorectal cancer;World Journal of Gastrointestinal Oncology;2020-08-15

3. Comparison of rates of adherence to oral chemotherapy medications filled through an internal health-system specialty pharmacy vs external specialty pharmacies;American Journal of Health-System Pharmacy;2020-06-15

4. Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis;European Journal of Surgical Oncology (EJSO);2017-01

5. Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer;Chinese Journal of Cancer;2016-01-06